Transgene

Transgene, part of Institut Mérieux, is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancers and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.

The Company’s lead clinical-stage programs are: TG4010 for non-small cell lung cancer, Pexa-Vec for liver cancer and TG4001 for HPV-positive head and neck cancers. The Company has several other programs in clinical and pre-clinical development.

Transgene also owns Invir.IO(TM), a new technology platform dedicated to the design of the next generation of oncolytic viruses. These multifunctional viruses are aimed at modulating the tumor micro-environment.

The Company is based in Strasbourg, France, and has additional operations in Lyon, in China and in the U.S.